EE200300260A - Kondenseeritud puriinderivaadid kui A1 adenosiiniretseptori antagonistid - Google Patents

Kondenseeritud puriinderivaadid kui A1 adenosiiniretseptori antagonistid

Info

Publication number
EE200300260A
EE200300260A EEP200300260A EEP200300260A EE200300260A EE 200300260 A EE200300260 A EE 200300260A EE P200300260 A EEP200300260 A EE P200300260A EE P200300260 A EEP200300260 A EE P200300260A EE 200300260 A EE200300260 A EE 200300260A
Authority
EE
Estonia
Prior art keywords
receptor antagonists
adenosine receptor
purine derivatives
condensed purine
condensed
Prior art date
Application number
EEP200300260A
Other languages
English (en)
Inventor
Lin Ko-Chung
Vu Chi
Original Assignee
Biogen, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen, Inc. filed Critical Biogen, Inc.
Publication of EE200300260A publication Critical patent/EE200300260A/et

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
EEP200300260A 2000-12-01 2001-11-30 Kondenseeritud puriinderivaadid kui A1 adenosiiniretseptori antagonistid EE200300260A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25065800P 2000-12-01 2000-12-01
PCT/US2001/044991 WO2002044182A1 (en) 2000-12-01 2001-11-30 Condensed purine derivatives as a1 adenosine receptor antagonists

Publications (1)

Publication Number Publication Date
EE200300260A true EE200300260A (et) 2003-08-15

Family

ID=22948640

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200300260A EE200300260A (et) 2000-12-01 2001-11-30 Kondenseeritud puriinderivaadid kui A1 adenosiiniretseptori antagonistid

Country Status (33)

Country Link
US (2) US6605601B2 (et)
EP (1) EP1347981B1 (et)
JP (2) JP2004514723A (et)
KR (1) KR20040011439A (et)
CN (1) CN100497340C (et)
AR (1) AR035400A1 (et)
AT (1) ATE394402T1 (et)
AU (2) AU1997702A (et)
BG (1) BG107849A (et)
BR (1) BR0115833A (et)
CA (1) CA2430508C (et)
CZ (1) CZ20031513A3 (et)
DE (1) DE60133931D1 (et)
EA (1) EA009814B1 (et)
EE (1) EE200300260A (et)
ES (1) ES2305139T3 (et)
GE (1) GEP20094697B (et)
HK (1) HK1059927A1 (et)
HU (1) HUP0400530A3 (et)
IL (1) IL156046A0 (et)
IS (1) IS6821A (et)
MX (1) MXPA03004857A (et)
MY (1) MY127120A (et)
NO (1) NO20032483L (et)
NZ (1) NZ526511A (et)
PL (1) PL362642A1 (et)
SK (1) SK6552003A3 (et)
TR (1) TR200300766T2 (et)
TW (1) TWI293301B (et)
UA (1) UA75625C2 (et)
WO (1) WO2002044182A1 (et)
YU (1) YU42903A (et)
ZA (2) ZA200304067B (et)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE289311T1 (de) * 1999-12-24 2005-03-15 Kyowa Hakko Kogyo Kk Kondensierte purinderivate
CA2430508C (en) * 2000-12-01 2010-05-18 Biogen, Inc. Condensed purine derivatives as a1 adenosine receptor antagonists
CA2516250A1 (en) * 2003-02-19 2004-09-02 Endacea, Inc. A1 adenosine receptor antagonists
US20040229901A1 (en) * 2003-02-24 2004-11-18 Lauren Otsuki Method of treatment of disease using an adenosine A1 receptor antagonist
AU2004233852A1 (en) * 2003-04-25 2004-11-11 Novacardia, Inc. Method of improved diuresis in individuals with impaired renal function
KR20060005376A (ko) * 2003-04-25 2006-01-17 교와 핫꼬 고교 가부시끼가이샤 축합 피리미딘 유도체
EP1636229A4 (en) * 2003-06-06 2008-07-30 Endacea Inc ADENOSINE A1 RECEPTOR ANTAGONISTS
MX2007010984A (es) * 2005-03-11 2008-03-18 Aderis Pharmaceuticals Inc 9-alquiladeninas sustituidas y uso de las mismas.
US7795427B2 (en) * 2006-02-14 2010-09-14 New York University Methods for inhibiting osteoclast differentiation, formation, or function and for increasing bone mass
JP2009532479A (ja) * 2006-04-06 2009-09-10 ノヴァカーディア，インク． アデノシンａ１受容体アンタゴニストと抗痙攣薬の同時投与
ES2525076T3 (es) 2006-05-19 2014-12-17 Abbvie Bahamas Ltd. Derivados de alcanos azabicíclicos sustituidos con bicicloheterociclos condensados activos en el SNC
WO2007149366A1 (en) * 2006-06-16 2007-12-27 Novacardia, Inc. Prolonged improvement of renal function comprising infrequent administration of an aa1ra
AR061626A1 (es) 2006-06-23 2008-09-10 Incyte Corp Derivados de purinona como agonistas de hm74a
AR061625A1 (es) 2006-06-23 2008-09-10 Incyte Corp Derivados de purinona como agonistas de hm74a
US20090197900A1 (en) * 2007-03-29 2009-08-06 Howard Dittrich Methods of treating heart failure and renal dysfunction in individuals with an adenosine a1 receptor antagonist
WO2008121882A1 (en) * 2007-03-29 2008-10-09 Novacardia, Inc. Improved methods of administration of adenosine a1 receptor antagonists
WO2011063268A2 (en) * 2009-11-19 2011-05-26 Biogen Idec Ma Inc Novel synthetic methods
US20130109645A1 (en) 2010-03-31 2013-05-02 The united States of America,as represented by Secretary,Dept.,of Health and Human Services Adenosine receptor agonists for the treatment and prevention of vascular or joint capsule calcification disorders
KR20200106176A (ko) 2018-01-04 2020-09-11 임페티스 바이오사이언시즈 엘티디. 삼환식 화합물, 삼환식 화합물을 포함하는 조성물 및 이의 의약적 용도

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06102662B2 (ja) 1989-09-01 1994-12-14 協和醗酵工業株式会社 キサンチン誘導体
EP0423805B1 (en) 1989-10-20 2000-08-23 Kyowa Hakko Kogyo Kabushiki Kaisha Condensed purine derivatives
DK1193252T3 (da) 1991-09-23 2007-04-30 Univ Florida State Beta-lactamer der er anvendelige til fremstilling af substituerede isoserinestere under anvendelse af metalalkoxider
AU4471297A (en) * 1996-10-07 1998-05-05 Kyowa Hakko Kogyo Co. Ltd. Fused purine derivatives
JP2002505687A (ja) * 1997-06-18 2002-02-19 ディスカバリー セラピューティクス，インコーポレイテッド 脈管再生手順の後の再狭窄を防止するための組成物および方法
CA2336412C (en) * 1998-07-02 2007-11-27 Junichi Shimada Medicament for treatment of diabetes
ATE289311T1 (de) * 1999-12-24 2005-03-15 Kyowa Hakko Kogyo Kk Kondensierte purinderivate
CA2430508C (en) * 2000-12-01 2010-05-18 Biogen, Inc. Condensed purine derivatives as a1 adenosine receptor antagonists

Also Published As

Publication number Publication date
US20030220358A1 (en) 2003-11-27
MY127120A (en) 2006-11-30
ATE394402T1 (de) 2008-05-15
CA2430508C (en) 2010-05-18
HUP0400530A3 (en) 2007-05-29
PL362642A1 (en) 2004-11-02
IL156046A0 (en) 2003-12-23
HUP0400530A2 (hu) 2004-06-28
ZA200408755B (en) 2005-07-27
TWI293301B (en) 2008-02-11
IS6821A (is) 2003-05-20
EA009814B1 (ru) 2008-04-28
NO20032483L (no) 2003-07-30
EP1347981A1 (en) 2003-10-01
SK6552003A3 (en) 2003-12-02
KR20040011439A (ko) 2004-02-05
CN1481387A (zh) 2004-03-10
AR035400A1 (es) 2004-05-26
NZ526511A (en) 2005-04-29
TR200300766T2 (tr) 2004-09-21
DE60133931D1 (de) 2008-06-19
ZA200304067B (en) 2005-05-30
WO2002044182A1 (en) 2002-06-06
UA75625C2 (en) 2006-05-15
YU42903A (sh) 2006-05-25
CZ20031513A3 (cs) 2003-09-17
US6605601B2 (en) 2003-08-12
AU1997702A (en) 2002-06-11
BR0115833A (pt) 2003-10-28
EP1347981B1 (en) 2008-05-07
JP2010053148A (ja) 2010-03-11
ES2305139T3 (es) 2008-11-01
AU2002219977B2 (en) 2008-01-24
CN100497340C (zh) 2009-06-10
GEP20094697B (en) 2009-06-10
NO20032483D0 (no) 2003-06-02
CA2430508A1 (en) 2002-06-06
US20020111333A1 (en) 2002-08-15
EA200300629A1 (ru) 2003-12-25
JP2004514723A (ja) 2004-05-20
HK1059927A1 (en) 2004-07-23
US7022686B2 (en) 2006-04-04
MXPA03004857A (es) 2003-08-19
BG107849A (bg) 2004-01-30

Similar Documents

Publication Publication Date Title
EE200300260A (et) Kondenseeritud puriinderivaadid kui A1 adenosiiniretseptori antagonistid
ATE293627T1 (de) Adenosin a2a rezeptor antagonisten
ATE317844T1 (de) Adenosine a2a receptor antagonisten
IS5706A (is) Adenosín A3 viðtakastillar
PT1309559E (pt) Derivados de 4-fenil-piridina como antagonistas do receptor de neuroquinina-1
IL178396A0 (en) Condensed pyridine derivatives useful as a28 adenosine receptor antagonists
DE60234951D1 (de) Adenosin a2a rezeptor antagonisten
HUP0401925A3 (en) A2b adenosine receptor antagonists
DE60219196D1 (de) BICYCLISCHE Ä1,2,4ö-TRIAZOL ADENOSIN A2a REZEPTOR ANTAGONISTEN
IL153837A0 (en) 4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists
NO20020931D0 (no) Pyrrolo[2,3-d]pyrimidin-nukleosid-analoger
NO20020979L (no) Selektive A2B-adenosinreseptorantagonister
NO20015662L (no) Oralt aktive A1-adenosinreseptorantagonister
ATE338043T1 (de) 5-methoxy-8-aryl- 1,2,4ötriazolo 1,5-aöpyridine derivative als adenosin-rezeptor antagonisten
EP1636230A4 (en) ADENOSINE A1 RECEPTOR ANTAGONISTS
SI1401837T1 (sl) Purinski derivati kot antagonisti adenozinskega receptorja A2B
SI1444233T1 (sl) Antagonisti adenozinskega receptorja A2B
SE0003996D0 (sv) Receptorantagonister

Legal Events

Date Code Title Description
HC1A Change of owner name